PRESS-RELEASE

FOR IMMEDIATE DISTRIBUTION

14 TH SEPTEMBER 2011OJSC “VEROPHARM” ANNOUNCES FINANCIAL RESULTSFOR THE FIRST HALF OF 2011 YEAR (UNAUDITED)

SEPTEMBER 14, 2011, MOSCOW – OJSC “VEROPHARM” [RTS:VRPH, MICEX:VFRM] announces its unaudited financial results for the 1st Half 2011 in accordance with the International Financial Reporting Standards (IFRS).

SALES

- Consolidated sales in H1 2011 increased by 18.0% and reached RUR 3,154.8 million (as compared with RUR 2,673.2 million in H1 2010).

Group of pharmaceutical products

o Rx drugs sales amounted to RUR 2,189.4 million, a 16.4% increase in comparison with H1 2010. The Rx drugs sales accounted for 69.4% of total finished goods sales. [1]

o OTC drugs sales amounted to RUR 392.6 million, a 32.2% increase in comparison with H1 2010. The share of OTC drugs makes 12.5% of total finished goods sales.

o Traditional drug sales amounted to RUR 13.7 million, which represents a 55.1% decrease as compared to H1 2010. The share of traditional drugs in total sales decreased to 0.4%

Group of non-pharmaceutical products

o Adhesive bandages and cosmetic products sales came to RUR 559.1 million, a

20.3% increase in comparison with H1 2010. The share of adhesive bandages and cosmetic products in total finished goods sales of the Company was 17.7%.

Veropharm sales as part of the Federal Reimbursement Program (FRP) came to RUR

79,1 million, accounting for 2,5% of the Company’s total finished goods sales. [1]

In H1 2011 sales within the Russian Federation provided 97% of the